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Abstract
Increased fatty acid (FA) is often observed in highly proliferative tumors. FAs have been shown to modulate the
secretion of proteins from tumor cells, contributing to tumor survival. However, the secreted factors affected by FA
have not been systematically explored. Here, we found that treatment of oleate, a monounsaturated omega-9 FA,
promoted the proliferation of HepG2 cells. To examine the secreted factors associated with oleate-induced cell
proliferation, we performed a comprehensive secretome proﬁling of oleate-treated and untreated HepG2 cells.
A comparison of the secretomes identiﬁed 349 differentially secreted proteins (DSPs; 145 upregulated and 192
downregulated) in oleate-treated samples, compared to untreated samples. The functional enrichment and network
analyses of the DSPs revealed that the 145 upregulated secreted proteins by oleate treatment were mainly associated
with cell proliferation-related processes, such as lipid metabolism, inﬂammatory response, and ER stress. Based on
the network models of the DSPs, we selected six DSPs (MIF, THBS1, PDIA3, APOA1, FASN, and EEF2) that can
represent such processes related to cell proliferation. Thus, our results provided a secretome proﬁle indicative of an
oleate-induced proliferation of HepG2 cells.
Introduction
Various factors are secreted from tumor cells, as well as
other types of cells interacting with tumor cells, con-
tributing to promoting or inhibiting tumor growth and
survival. A number of proteomic analyses of secretomes
have been performed for pancreatic, breast, prostate,
bladder, and liver cancers1–5 to catalog the factors
secreted from tumor cells. These analyses have mainly
focused on the identiﬁcation of proteins differentially
secreted between tumor and normal cells and then pro-
posed these proteins as potential diagnostic biomarkers
for the cancers analyzed. However, tumor secretomes
vary with different pathophysiological conditions, thereby
altering tumor growth, survival, and/or invasion. A
comparative proteomic analysis of tumor secretomes
between different pathophysiological conditions has rarely
been performed to understand alterations in the secreted
factors associated with cancer pathogenesis.
Fatty acids (FAs) have been reported to affect the
secretomes from tumors6–8. For example, linoleic acid
enhanced the secretion of the plasminogen activator
inhibitor-1 in breast cancer6, and oleate, a mono-
unsaturated omega-9 FA, induced the secretion of matrix
metallopeptidase 9 in breast cancer cells to promote
their invasiveness7. Additionally, palmitate increased the
secretion of interleukin-8 in steatotic hepatoma cells8,
providing a higher potential for hepatic inﬂammation.
Among the FAs, oleate was reported to be the most
abundant circulating free FA in mammals9–13, and its
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level is often increased in cancer tissues14. The effect
of oleate on the proliferation of cancer cells has
been controversial. Many studies showed that oleate
promoted the proliferation of cancer cells in various types
of cancers15,16, but other studies showed the opposite
effect. These contradictory observations are probably due
to the differences in types of cancer cells, degree of
malignancy, growth conditions, and/or even assay meth-
ods. Nevertheless, it has been consistently observed that
oleate has substantial effects on the growth and survival
of cancer cells. As aforementioned, oleate modulates
the secretion of proteins from tumor cells, including
cytokines and chemokines, which can contribute to the
proliferation of cancer cells.
Accordingly, the investigation of secretory factors
modulated by oleate is important to understand the
effect of oleate on cell proliferation. However, these
secretory factors affected by oleate still remain elusive.
Here, to examine secretory factors affected by oleate,
we performed a comparative secretome analysis of hepa-
tocarcinoma HepG2 cells by proﬁling the proteomes
of conditioned media collected with and without
oleate treatment, using label-free liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis.
HepG2 cells were used because they have been shown to
secrete a broad spectrum of molecules (e.g., proteins and
metabolites)17–19 and are widely used for various studies,
including mechanism studies, drug screening, and secre-
tome analysis15,20–22. The comparative secretome analysis
of oleate-treated and untreated HepG2 cells identiﬁed
349 differentially secreted proteins (DSPs) by oleate
treatment that are associated with cellular processes
related to cell proliferation. Thus, our proteome data
provide a secretome proﬁle that can represent the
cellular processes related to oleate-induced proliferation
of HepG2 cells.
Materials and methods
Reagents and cell culture
Sodium oleate (O7501, St. Louis, MO) and
sodium palmitate (P9767, St. Louis, MO) were pur-
chased from Sigma-Aldrich. Bovine serum albumin,
fraction V, and fatty acid-free (126575, San Diego, CA)
was purchased from Calbiochem. Oleate or palmitate
was dissolved in 100% methanol. After conjugation with
fatty-acid-free BSA at a 5:1 fatty acid to BSA molar
ratio, as previously described23, it was diluted to a
proper ﬁnal concentration in serum-free Minimum
Essential Medium (MEM) just before the treatment of
cells. HepG2 cells were grown in MEM (Welgene,
LM 007-07) and then supplemented with 10% (v/v)
fetal bovine serum (Lonza), 2 mM glutamine, and 1%
penicillin-streptomycin (Gibco) at 37 °C, 5% CO2, and
95% humidity.
Cell proliferation assays
Cell proliferation was measured by a colorimetric assay
for cell viability using MTT (Sigma Aldrich, M5655).
HepG2 cells were seeded in a 96-well culture plate and
incubated for 24 h. After starvation with unsupplemented
media for 12 h, cells were incubated with fatty acids
treatment for 24 h, as done for the sample preparation of
the secretome analysis. For control samples, cells were
incubated with the equivalent concentrations of methanol
and BSA contained in the fatty acid treatment conditions.
Cells were treated with 0.5 mg/ml MTT reagent that
was diluted in phenol-red-free media and incubated in a
37 °C CO2 incubator. After 2 h, the solution was replaced
with 100 μl of DMSO to solubilize formazan crystals. The
intensity was measured in plates at 540 nm absorbance
by using a microplate reader.
Sample preparation
HepG2 cells were starved for 12 h before fatty acid
treatment. To eliminate secretory factors from cells
during starvation, cells were washed three times with
1× PBS. For oleate-treated samples, BSA-conjugated
oleate diluted to a ﬁnal concentration of 500 μM in
serum-free media was treated for 24 h. For control sam-
ples, oleate-free serum-free medium containing equiva-
lent amounts of BSA and methanol used for oleate-treated
samples was treated for 24 h. The conditioned media were
prepared by replacing the media with unsupplemented
serum-free media and incubating for 24 h in a 37 °C CO2
incubator. After centrifuging the conditioned media
at 3000 r.p.m. for 10min at 4 °C, only supernatants
were collected and ﬁltered using centrifugal ﬁlter units
(Millipore, UFC900324) to remove contaminants. Sam-
ples were dried by utilizing a lyophilizer.
Protein extraction and digestion
The samples were dried and then homogenized with
lysis buffer (urea, NaCl, 50mM Tris-HCl (pH 8.2) and a
Complete Mini protease inhibitor tablet (Roche Applied
Science, Basel, Switzerland)). The lysate was ultra-
centrifuged at 45,000×g at 4 °C for an hour. The protein
concentration was determined from the resulting super-
natant by the DC protein assay (Bio-Rad, Hercules, USA).
The protein sample was then reduced in 0.5M DTT
(100 µl) for 50min at 37 °C, followed by addition of 1.5 µl
of 1M iodoacetamide and incubation in the dark for
30min at room temperature for alkylation. The resulting
sample was subjected to in-solution tryptic digestion
(1:50 enzyme-to-protein ratio (w/w), Promega, Madison,
WI, USA) and then incubated at 37 °C overnight. The
peptide samples were centrifuged at 2500×g for 10min at
room temperature. The resulting aqueous solution was
desalted using solid-phase extraction with reverse-phase
tC18 Sep-Pak solid-phase extraction cartridges as
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previously described24. Finally, the peptides were eluted
with 50% ACN and 0.5% HAcO and then dried in a Speed-
Vac with resuspension in 0.1% formic acid. The samples
were stored at −20 °C before LC-MS/MS analysis.
LC-MS/MS analysis
All peptide samples were separated on a Thermo
EASY-nLC 1000 (Thermo Scientiﬁc, Odense, Denmark)25
equipped with analytical columns (Thermo Scienti-
ﬁc, Easy-Column, 75 μm× 50 cm) and trap columns
(75 μm× 2 cm). The operation temperature of the analy-
tical columns was 50 °C. The ﬂow rate was set to 300 nl/
min. Solvent A was 0.1% formic acid and 2% acetonitrile
in water, and solvent B was 0.1% formic acid and 2% water
in acetonitrile. For the global proteome analysis, a 120-
min gradient (from 2 to 40% solvent B over 90min, from
40 to 80% solvent B over 10min, 80% solvent B for 10 min
and from 80 to 2% solvent B over 10min) was used. The
eluted peptides from LC were analyzed using the Q-
Exactive™ hybrid quadrupole-Orbitrap mass spectrometer
(Thermo Scientiﬁc)26 equipped with the nanoelectrospray
source. For ionization of the eluting peptides, the electric
potential of the electrospray ionization was kept at 1.7 kV,
and the temperature of the desolvation capillary was set
to 270 °C. The Q-Exactive mass spectrometer was oper-
ated in the data-dependent mode, with survey scans
acquired for the mass range of 450–2000 Thomsons (Th)
at a resolution of 70,000 (at m/z 200). The top 10 most
abundant ions from the survey scan were selected for
MS/MS analysis with an isolation window of 2.0 Th and
fragmented by the higher energy collisional dissociation
(HCD)27 with the normalized collision energies of 25 and
the exclusion duration of 10 s. The MS/MS scans were
acquired at a resolution of 17,500. Maximum ion injection
times were 100ms and 50ms for the full MS and the
MS/MS scan, respectively. The automated gain control
(AGC) target value was set to 1.0 × 106 and 1.0 × 105 for
the full MS and MS/MS scan, respectively.
Peptide identiﬁcation
The fragmentation spectra were created based on the
mzXML ﬁle using the MSConvert tool (ProteoWizard
release: 3.0.4323). MS data were ﬁrst analyzed using
postexperiment-monoisotopic mass reﬁnement (PE-
MMR) to assign an accurate precursor mass to tandem
MS data28. MS/MS spectra were searched against a
composite database containing UniProtKB/Swiss-Prot
entries of the human reference proteome (UniProtKB
release 2015_11, 42,123 entries) and 179 common
contaminants in the target-decoy setting using the
MS-GF+ Beta (v10089) search engine29 under the fol-
lowing parameters: semitryptic, precursor mass tolerance
of 10 p.p.m., carbamidomethylation of cysteine as a ﬁxed
modiﬁcation and oxidation of methionine as a variable
modiﬁcation. The search results of 24 LC-MS/MS data-
sets were all combined, and the target-decoy analysis was
performed on the combined dataset to obtain peptides
with the false discovery rate (FDR) ≤ 0.01.
Label-free peptide quantiﬁcation
To assign an MS intensity to peptide identiﬁcation, an
MS intensity-based label-free quantiﬁcation method was
applied to 24 LC-MS/MS datasets as described pre-
viously30. Brieﬂy, through PE-MMR analysis, MS features
of a peptide that appeared over a period of LC elution
time in an LC-MS/MS experiment were grouped into a
unique mass class (UMC)28. Ideally, each UMC corre-
sponds to a peptide and contains the ions corresponding
to the peptide, together with their mass spectral features,
such as charge states, abundances (intensity), scan num-
bers, and measured monoisotopic masses. For each UMC,
we obtained the UMC mass by calculating the intensity-
weighted average of the monoisotopic masses of all the
ions in the UMC. For the peptide corresponding to the
UMC, its abundance was estimated as the summation of
the abundances of all the ions in the UMC (UMC inten-
sity). The reﬁned precursor masses of the MS/MS spectra
by PE-MMR were matched to the UMC masses and then
were replaced with those of UMCs. In this process,
MS/MS spectra information was linked to the matched
UMC. The linked MS/MS spectra were assigned with a
peptide sequence (peptide ID) with an FDR ≤ 0.01 after
MS-GF+ searching and target-decoy analysis. The pep-
tide ID was assigned to the UMC, and the UMC intensity
was assigned to the peptide ID.
Assignment of UMCs by a master accurate mass
and time tag database
To assign the peptide IDs to unidentiﬁed UMCs, the
master accurate mass and time tag (AMT) database (DB)
was constructed and utilized as described previously31.
Brieﬂy, the information about UMCs with peptide IDs
from 24 LC-MS/MS data (triplicate LC-MS/MS experi-
ments of 8 samples) was compiled into the master AMT
DB. The AMTs are unique peptide sequences whose
monoisotopic masses and normalized elution times
(NETs)32 are experimentally determined. For each AMT
whose corresponding peptides were measured multiple
times, the average mass and the median NET were
recorded. We then mapped unidentiﬁed UMCs to AMTs
in the master AMT DB with ±10 p.p.m. of mass and ±0.02
of NET tolerances. After an unidentiﬁed UMC was found
to be mapped to an AMT using the mass and NET
tolerances, we further computed a Xcorr measure to
evaluate the similarity between their MS/MS spectra.
Finally, the unidentiﬁed UMC was decided to be matched
to the AMT when Xcorr was larger than the cutoff of 3.0.
For each unidentiﬁed UMC matched to an AMT, the
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peptide ID for the AMT was assigned to the unidentiﬁed
UMC, together with all information for the AMT (UMC
mass and NET).
Alignment of the identiﬁed peptides
After the assignment of unidentiﬁed UMCs using
the master AMT DB, we combined the assigned and
identiﬁed UMCs from LC-MS/MS datasets into an nm
alignment table (peptide IDs for n UMCs and UMC
intensities in m samples). The missing value in the
alignment table means that the peptide was not identi-
ﬁed in the corresponding datasets. For the missing
values in each row of the table, we further searched for
the UMCs that could be matched to the aligned UMCs
based on their UMC masses and NETs with the
following tolerance: ±10 p.p.m. and ±0.01 across the
technical replicates, and ±10 p.p.m. and ±0.02 across
the biological replicates, respectively. Quantile normal-
ization was performed for UMC intensities in the
alignment table to correct systematic variations of
peptide abundances across datasets33. To evaluate the
reproducibility of LC-MS/MS analysis, two types of
similarity scores between LC-MS/MS datasets were
calculated by measuring the overlap of the detected
peptides and their intensity values, as previously
described34.
Identiﬁcation of differentially secreted proteins
To identify differentially secreted proteins (DSPs), we
ﬁrst selected differentially expressed peptides (DEpep-
tides) by applying a previously reported integrative sta-
tistical method35 to the UMC (peptide) intensities in the
alignment table. Brieﬂy, log2-intensities of each peptide in
the oleate-treated samples were compared to those of the
untreated controls by Student’s t-test and the median-
ratio test, which resulted in a T value and log2-median
ratio, respectively, for each peptide. We then estimated
empirical null distributions of T values and log2-median
ratios by randomly permuting 24 samples 1000 times. For
each peptide, the adjusted P values of the observed T
value and log2-median ratio were computed using the
empirical distributions with a two-tailed test and then
integrated into an overall P value by using Stouffer’s
method36. The DEpeptides were identiﬁed as the peptides
that were detected in at least six samples for either of the
conditions, with their overall P < 0.05 and absolute log2-
fold-change ≥95th percentile of the empirical null dis-
tribution of log2-fold-changes. Moreover, we additionally
selected as DEpeptides the peptides whose intensities
were missing in all samples under one condition but
present in at least six under the other condition. Finally,
the proteins with the numbers of upregulated or down-
regulated unique DEpeptides ≥2 were identiﬁed as upre-
gulated or downregulated DSPs, respectively.
Functional enrichment analysis of detected proteins
or DSPs
The enrichment analysis of Gene Ontology biological
processes (GOBPs) or Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways for a list of proteins (detected
proteins or DSPs) was performed using DAVID soft-
ware37. GOBPs represented by the list of proteins were
identiﬁed as those with P < 0.01. P values of the processes
were then converted to Z-scores for visualization using
Z= -N−1(P), where N−1 is the inverse standard normal
distribution.
Western blotting
For western blotting, HepG2 cells were harvested in
lysis buffer (10 mM Tris-HCl, pH 7.4, 1.5 mM EDTA, 10%
Glycerol) containing a protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, USA). After sonication and
centrifugation, the protein concentration was determined
by the Bradford reagent assay. Finally, SDS sample buffer
was mixed with lysate. Secretome samples were dissolved
in lysis buffer after lyophilization to the same concentra-
tion and mixed with SDS sample buffer. The samples
were separated on a 6–16% gradient SDS-PAGE gel and
transferred to a nitrocellulose membrane using the
Hoefer wet transfer system. After blocking with TBS-T
containing 5% skim milk for 30min, immunoblotting
was performed with primary antibodies at 4 °C overnight,
followed by incubation with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit antibody for 1 h.
The membranes were washed with TBS-T buffer and
developed using ECL solution. Western blotting was
performed in more than four biological replicates (n ≥ 4)
with the antibodies against PDIA3 (Abcam, Cambridge,
UK), APOA1 (Abcam, Cambridge, UK), THBS1 (Thermo
Fisher Scientiﬁc, MA, USA), MIF (Thermo Fisher Scien-
tiﬁc, MA, USA), FASN (Abcam, Cambridge, UK), and
EEF2 (Abcam, Cambridge, UK).
Data availability
The mass spectrometry proteomics data have been
deposited at the ProteomeXchange Consortium via the
PRIDE38 (Dataset identiﬁer PXD007906 and 10.6019/
PXD007906).
Results
Secretome proﬁling of oleate-treated HepG2 cells
We ﬁrst treated HepG2 cells with oleate for 24 h after
serum starvation for 12 h and then measured the growth
of HepG2 cells using an MTT assay. Oleate-treated
HepG2 cells showed enhanced cell proliferation, com-
pared to the untreated controls (Fig. 1a). This observation
was consistent with previous ﬁndings15,16, despite the
contradictory results in several studies, as previously
discussed in the Introduction (Discussion). Previously,
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palmitate, the most common saturated FA, was shown to
inhibit the proliferation of cancer cells by activating
apoptosis39–41. To conﬁrm the positive effect of oleate
on the proliferation of HepG2 cells, we cotreated oleate
with palmitate (500 μM) and then measured the growth
of HepG2 cells. We found that oleate rescued palmitate-
induced apoptosis of HepG2 cells at higher concentra-
tions of oleate than 100 μM, which indicates an anti-
apoptotic effect of oleate, thus supporting the increased
proliferation of HepG2 cells by oleate (Fig. 1b). Collec-
tively, these observations suggest that the treatment of
the high concentration of oleate (500 μM) caused no
signiﬁcant lipotoxicity that can lead to apoptosis of
HepG2 cells.
To examine secreted proteins from HepG2 that could
contribute to an increased proliferation of HepG2 cells,
we performed secretome proﬁling of HepG2 cells with
and without treatment of oleate (Fig. 1c). To this end, we
cultured four biological replicate samples (n= 4) inde-
pendently prepared with and without oleate treatment.
The supernatants collected from the culture media were
then subjected to in-solution protein digestion42 (Meth-
ods and materials). For the peptide sample from each
replicate in the oleate-treated and untreated conditions,
we performed label-free LC-MS/MS analysis with three
technical replicates (m= 3) as previously described31,
resulting in a total of 24 LC-MS/MS datasets, 12
(n ×m= 12) datasets for oleate-treated and untreated
conditions, respectively (Fig. 1c and Supplementary
Fig. S1). Since we analyzed the conditioned media, the
resulting proteome, referred to as the ‘secretome’ in this
study, can include secretory proteins, as well as proteins
shed from the cell surface or proteins leaked from dying
cells. However, the anti-apoptotic effect of oleate (Fig. 1b)
suggests that proteins leaked from apoptotic cells are
unlikely to be enriched in our secretome (Discussion).
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Fig. 1 Cell proliferation assay and secretome proﬁling of oleate-treated and untreated HepG2 cells. a, b MTT assays for measuring
proliferation of HepG2 cells after treatment with different concentrations (50, 100, 250, 500, and 1000 μM) of oleate (a) and after cotreatment with
palmitate (500 μM) and oleate (0, 100, 250, or 500 μM) (b). The data are shown as the mean ± SEM (n= 4). *P < 0.05 by Student’s t-test. The dashed
line denotes the threshold of relative proliferation= 1. c An overall scheme for the secretome proﬁling. HepG2 cells were subjected to serum
starvation for 12 h and then treated with oleate (500 μM). Oleate-treated (n= 4) and untreated (n= 4) samples were incubated for 24 h with
conditioned media, and supernatants from the conditioned media were collected for sample preparation. LC-MS/MS analyses were performed
for Peptide samples from oleate-treated and untreated samples with three technical replicates. The resulting LC-MS/MS datasets were analyzed using
PE-MMR analysis, MS-GF+ search, and AMT DB analysis for identiﬁcation, assignment, and alignment of UMCs (see text)
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Next, peptide identiﬁcation was performed for 24 LC-
MS/MS datasets using PE-MMR analysis followed
by an MS-GF+ search with the target-decoy strategy
(FDR ≤ 0.01; Supplementary Table S1a). All identiﬁed
UMCs (peptides) from the 24 datasets were used
to construct the master AMT DB that comprised 30,933
peptides (or AMTs; Supplementary Table S2). Using
the AMT DB, unidentiﬁed UMCs in the individual sam-
ples were matched with the peptides in the DB using the
mass and the NET tolerances (Methods and materials)
and then assigned with IDs of the matched peptides
(Supplementary Table S1b). After the AMT DB search,
the peptides were quantiﬁed as their UMC intensities in
the 24 LC-MS/MS datasets and then compiled into an
alignment table (Fig. 1c; Methods and materials). Using
peptide abundances (UMC intensities) normalized by
quantile normalization33, we ﬁrst examined the reprodu-
cibility of our label-free LC-MS/MS analysis using the ID
and intensity similarity scores described by Mueller
et al34. The average ID and intensity similarity scores in
the 24 LC-MS/MS datasets were found to be 0.94 and
0.90, respectively, suggesting high reproducibility of the
label-free LC-MS/MS analysis (Supplementary Fig. S2).
Based on the 30,933 peptides in the AMT DB, we iden-
tiﬁed 2640 HepG2 secretory proteins (2630 protein-
coding genes) with high conﬁdence as the proteins with
two or more sibling unique peptides (Supplementary
Table S3).
Comparison of the measured secretome with previous
secretomes
To assess the comprehensiveness of our secretome,
we compared the 2630 detected protein-coding genes with
(1) two human plasma secretomes previously reported43,44
and (2) the 4007 genes whose cellular localization was
annotated with ‘extracellular region’ based on Gene
Ontology cellular compartments (GOCCs) (Fig. 2a). The
two human plasma secretomes reported by Farrah et al43.
and Uhlén et al44. included the proteins encoded from
1803 and 2697 genes, respectively. Of the 2630 protein-
coding genes in our secretome, 1402 (2630−1228= 1402
in Fig. 2a; 53.3%) were detected in at least one of the two
plasma secretomes or annotated with an extracellular
region based on GOCCs. Next, we further compared our
secretome with two liver cancer secretomes previously
reported4,45 (Fig. 2b). Wu et al4. proﬁled the secretomes
of three liver cancer cell lines (HepG2, Hep3B, and
SK-Hep-1), which included 2116 protein-coding genes.
Additionally, Li et al45. proﬁled the N-glyco-secretomes of
two liver cancer cell lines (MHCC97-L and HCCLM3),
which included 553 protein-coding genes. Of the 2630
protein-coding genes in our secretome, 1312 genes
(2630–1318= 1312 in Fig. 2b; 49.9%) were shared with the
two liver cancer secretomes. Taken together, of the 2630
protein-coding genes in our secretome, 1766 genes (67.1%)
were detected in either the human plasma or the liver
cancer secretomes (Fig. 2c), which supports the validity
of our secretome. The remaining 864 nonoverlapping
genes were newly identiﬁed in our study as the ones
whose protein products are to be secreted (Fig. 2c), which
suggests the comprehensiveness of our secretome.
Next, we examined GOCCs enriched by the 1766
overlapping protein-encoding genes using DAVID
software37. Of the 1766 overlapping genes, 1224 were
localized in secretion-related GOCCs, such as the extra-
cellular region, plasma membrane, Golgi apparatus, and
endoplasmic reticulum (ER; Fig. 2d). Interestingly, on
the other hand, a signiﬁcant number (1201 genes) of
the 1766 overlapping genes were previously reported to
be localized in the cytosol, nucleus, or mitochondrion.
These data suggest a hypothesis that our secretome may
include the proteins in microvesicles released from
HepG2 cells. In support of this hypothesis, the 1201 genes
showed a signiﬁcant (57.6%) overlap with the exosome
proteome annotated by GOCCs (Supplementary Fig. S3).
Moreover, to examine cellular processes associated
with the 1766 overlapping genes, we performed the
enrichment analysis of GOBPs for the 1766 genes using
DAVID software (Fig. 2e and Supplementary Table S4).
The overlapping genes were signiﬁcantly (P < 0.01) asso-
ciated with secretion-related processes (protein transport,
extracellular matrix organization, vesicle organization,
actin cytoskeleton organization, and glycosylation), as
well as various cancer-related processes including cell
cycle (cell cycle, DNA repair, apoptotic process, and
mRNA metabolic process), immune responses (antigen
processing and presentation, chemotaxis, coagulation,
innate immune response, and cell migration), intracellular
signaling (phosphorylation and intracellular signal trans-
duction), protein homeostasis (translation, ribosome
biogenesis, protein folding, and protein ubiquitination),
and metabolism (carbohydrate and lipid metabolic pro-
cesses). These data suggest that our secretome includes
secreted proteins that can contribute to modulating the
processes related to cancer pathogenesis.
Secretome alterations by oleate treatment and its
associated processes
To determine secreted proteins whose abundances were
altered in HepG2 cells by oleate treatment, we ﬁrst
aligned the 30,933 quantiﬁed peptides in the 24 LC-MS/
MS datasets (12 oleate-treated and 12 untreated samples)
and then compared their abundances between oleate-
treated and untreated samples (Methods and materials).
For the aligned peptides, we identiﬁed 2461 unique pep-
tides (DEpeptides) showing signiﬁcant (P < 0.05) upregu-
lation or downregulation by oleate treatment using
the integrative statistical method previously reported35
Park et al. Experimental & Molecular Medicine  (2018) 50:93 Page 6 of 14
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
(Methods and materials). We then identiﬁed 349 DSPs
that have two or more DEpeptides showing consistent
upregulation or downregulation by oleate treatment as
previously described46 (Methods and materials). We
excluded 12 DSPs having both two or more upregulated
and downregulated DEpeptides. Of the remaining DSPs,
145 were upregulated by oleate treatment, while 192 were
downregulated (Supplementary Table S5).
To understand cellular functions associated with the
DSPs, the enrichment analyses of GOBPs and KEGG
pathways were performed for 145 upregulated and 192
downregulated secreted proteins using DAVID software.
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Fig. 2 Comparison of our secretome with the previous secretomes and localization and functional analysis of the secretome. a Comparison
of our secretome with human plasma secretomes previously reported and with protein-coding genes known to be localized in the extracellular
region based on their GOCCs. b Comparison of our secretome with two previously reported liver cancer secretomes. c 1766 secreted proteins
overlapped with human plasma or liver cancer secretomes. d Distribution of cellular localizations (GOCCs) of the overlapping secreted proteins. Bar
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The upregulated secreted proteins by oleate treatment
were signiﬁcantly (P < 0.01) associated with the following
processes (Fig. 3a and Supplementary Table S6a): (i) lipid
transport and metabolism, (ii) inﬂammatory response
(complement and coagulation cascades, inﬂammatory
response, and response to wounding), (iii) cell adhesion
and migration (cell adhesion, cell migration, and extra-
cellular matrix organization), and (iv) unfolded protein
Fig. 3 Cellular processes represented by DSPs between oleate-treated and untreated samples and network models delineating key
cellular processes. a, b Cellular processes (GOBPs) enriched by upregulated (a) and downregulated (b) secreted proteins between oleate-treated
and untreated samples. Each bar represents the Z-score of the P value that is the signiﬁcance of the corresponding GOBP being enriched by
the DSPs. The dashed line denotes the cutoff of P= 0.01. Bar colors represent the groups of GOBPs associated with the indicated cellular events.
c–e Network models describing interactions among DSPs involved in FA removal and production (c), inﬂammatory responses and cell adhesion/
migration (d), and ER stress and protein degradation (e). Node colors represent up- (red) and down-regulation (green) of secreted proteins after
oleate treatment. Large nodes indicate the six secreted proteins selected as a secretome proﬁle in this study. Nodes were arranged according
to GOCCs and the localization information obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. Gray lines
represent protein-protein interactions, and the arrows and inhibition symbols obtained from the KEGG pathway database denote activation and
suppression, respectively. Thick black lines denote membranes, such as plasma membrane (PM), lysosomal (c) and ER (e) membranes, and vesicular
membranes (c)
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response (protein processing in ER, protein folding, pro-
teolysis, lysosome, and endocytosis). On the other hand,
the downregulated secreted proteins by oleate treatment
were associated with the following processes (Fig. 3b and
Supplementary Table S6b): (i) cell cycle (cell cycle and
apoptosis process), (ii) protein transport (protein trans-
port and actin cytoskeleton organization), (iii) protein
homeostasis (translation, tRNA aminoacylation, ribosome
biogenesis, protein ubiquitination, proteasome, and pro-
teolysis), (iv) carbon metabolism (insulin receptor sig-
naling and carbon metabolism), and (v) antigen
processing and presentation.
Cellular networks associated with the secretome altered
by oleate treatment
To understand the functions of the cellular processes
associated with upregulated and downregulated secreted
proteins, we next reconstructed a network model
describing the interactions among the DSPs involved in
their associated GOBPs mentioned above (Methods and
materials). The network model ﬁrst showed upregulation
of the following metabolic pathways contributing to FA
removal: (1) fatty acid degradation (ACAA2, HSD17B4,
and SCP2), (2) incorporation of triglyceride (TAG) into
pre-chylomicrons (MTTP, APOA4, and APOB), and (3)
chylomicron exocytosis or lipid efﬂux (RBP4, APOA1,
APOA4, APOB, APOH, and APOM) (Fig. 3c, center). In
contrast, it showed downregulation of the following
metabolic pathways contributing to FA production: (1) FA
synthesis (FASN, ACACA, and ACSL4), as well as (2)
glycolysis (HK2, PFKL, GAPDH, ENO1, and PKM) and
(3) the citrate cycle (MDH1 and IDH1), which contribute
to the generation of acetyl CoA, the precursor of FA
synthesis (Fig. 3c, right). Additionally, upregulation of the
metabolic pathways branching from the citrate cycle for
amino acid synthesis and oxidative phosphorylation also
contribute to the reduction of metabolic ﬂuxes for the
generation of acetyl-CoA. In addition, the network model
showed upregulation of lysosomal pathways involved in
lipophagy to remove lipid droplets formed by free FA and
TAG (Fig. 3c, left). All these alterations in the secretome
reﬂect that oleate treatment increases the intracellular FA
amount in HepG2 cells and thereby modulates metabolic
pathways to reduce the FA amount through increased FA
removal and decreased FA production. Moreover, the
network model showed upregulation of inﬂammatory
responses, including the complement and coagulation
pathway and neutrophil or platelet degranulation (Fig. 3d,
left). Additionally, it showed upregulation of ECM orga-
nization and cell adhesion and migration (Fig. 3d, right).
These alterations in the secretome suggest that oleate
treatment can contribute to inﬂammatory responses, as
well as cell adhesion and migration. Finally, the network
model showed upregulation of the unfolded protein
response pathway in the ER, consistent with the previous
ﬁnding that a nutrient excess derived by oleate treatment
contributes to the activation of ER stress47,48 (Fig. 3e, left).
In contrast, protein ubiquitination and proteasome
activities were downregulated (Fig. 3e, right). These
alterations in the secretome suggest that oleate treatment
can result in increased ER stress but decreased protein
degradation.
A secretome proﬁle associated with oleate-induced
proliferation of HepG2 cells
The network models above showed that inﬂammatory
responses (Fig. 3d), ER stress (Fig. 3e), and lipid meta-
bolism (Fig. 3c) were associated with the altered secre-
tome by oleate treatment. Previously, a number of studies
have reported associations of these processes with cell
proliferation. Thus, to select a secretome proﬁle that can
represent oleate-induced proliferation of HepG2 cells
(Fig. 1a), we focused on the DSPs involved in these pro-
cesses. First, for inﬂammatory response, oleate was shown
to induce anti-inﬂammatory responses49,50. The network
model showed an upregulation of molecules involved in
the anti-inﬂammatory response. Thus, we selected the
following representative secretome proteins for the anti-
inﬂammatory response in the network model (Fig. 3d):
(1) macrophage migration inhibitory factor (MIF) and
(2) thrombospondin 1 (THBS1). MIF inhibits inﬁltration
of macrophages51, and THBS1 is secreted and promotes
the resolution of inﬂammation52.
Second, nutrient starvation53,54 or excess47,48 in tumor
cells induces ER stress, which is the main site for trans-
lation of nutrition into metabolic and inﬂammatory
responses. A mild ER stress response is considered cyto-
protective, which is often accompanied by altered trans-
lation, contributing to tumor survival and adaptation
against harsh environments55–57. In our secretome, ER
stress response was upregulated together with down-
regulated translation (Fig. 3e). Thus, as the representative
DSPs for ER stress response-related processes in the
network model, we selected protein disulﬁde isomerase
family A member 3 (PDIA3) involved in the ER stress-
induced UPR response and eukaryotic translation elon-
gation factor 2 (EEF2) involved in translation (Fig. 3e).
Finally, in highly proliferative tumor cells, lipid-based
metabolic reprogramming is important for the supply of
energy and biomass components58. Lipid homeostasis
(lipid transport, biosynthesis, and degradation) has been
considered to be closely associated with the proliferation
of tumor cells59,60. In our secretome, lipid transport and
degradation were upregulated by oleate treatment, while
lipid biosynthesis was downregulated. Thus, as the
representative DSPs for oleate-induced alterations in lipid
metabolism, we selected apolipoprotein A1 (APOA1)
involved in lipid efﬂux and fatty acid synthase (FASN)
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involved in lipid biosynthesis (Fig. 3c). In total, the six
proteins mentioned above were selected as a secretome
proﬁle that can be associated with oleate-induced pro-
liferation of tumor cells.
To test the validity of the six selected proteins, we
cultured the samples independently prepared with and
without oleate treatment and collected the supernatants
from the culture media. In these new samples, using
western blotting, we then tested the upregulation or
downregulation of the selected secreted proteins. The
results showed that MIF, THBS1, PDIA3, and APOA1
were upregulated (Fig. 4a–d) and FASN and EEF2 were
downregulated (Fig. 4e–f) in oleate-treated samples,
compared to untreated samples, conﬁrming their differ-
ential expression measured by LC-MS/MS analysis after
oleate treatment. These data indicate that the six secreted
proteins can be used as a secretome proﬁle that represents
the oleate-induced proliferation of tumor cells.
Discussion
In liver cancer, the increased FA is a key feature of
highly proliferative tumors due to cancer-related meta-
bolic alterations. The secreted factors by the increased FA
can modulate the proliferation of tumor cells. A panel of
secreted factors can be used to assess FA-driven metabolic
reprogramming for tumor survival. However, the secreted
factors affected by the increased FA have not been sys-
tematically explored. In this study, we examined com-
prehensive secretome proﬁles affected by the increased
FA and identiﬁed a secretome proﬁle representing FA-
induced proliferation of tumor cells. To achieve this goal,
we employed an approach that involves (1) comprehen-
sive secretome proﬁling of a culture medium of HepG2
cells with and without oleate treatment; (2) identiﬁcation
of DSPs between oleate-treated and untreated samples;
(3) selection of a secretome proﬁle that can represent
cellular processes (lipid metabolism, inﬂammatory
response, and ER stress) associated with proliferation of
tumor cells; and (4) validation of the selected secretome
proﬁle in independent samples using western blotting.
Using this approach, we identiﬁed a secretome proﬁle
composed of six DSPs by oleate treatment (MIF, THBS1,
PDIA3, EEF2, APOA1, and FASN).
In this study, we found that oleate treatment promoted
the proliferation of HepG2 cells. However, there have
been conﬂicting reports regarding the effect of oleate on
the proliferation of HepG2 cells. Several studies showed
that oleate treatment led to the promotion of proliferation
of HepG2 cells15,16, but other studies reported that oleate
treatment reduced the proliferation of HepG2 cells and
induced apoptosis of HepG2 cells61. These contradictory
observations in these studies might be due to differences
in culture conditions, doses of oleate used, or states of the
cells. Moreover, the two previous studies mentioned
above15,16 showed that the high concentration of oleate
(500 µM) used in this study induced apoptosis of hepa-
toma cell lines. It can thus be speculated that the secre-
tome measured after oleate treatment may include a mix
of real secretion and necro-apoptotic content from
HepG2 cells. However, our further experiments showed
that palmitate-induced apoptosis of HepG2 cells was
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Fig. 4 Validation of upregulation and downregulation of the
selected secreted proteins after oleate treatment. a–f Western
blotting analysis of the six selected secreted proteins using an
independent set of the conditioned media samples (n ≥ 4): MIF (a),
THBS1 (b), PDIA3 (c), APOA1 (d), EEF2 (e), and FASN (f). The results
showed signiﬁcant (P < 0.05) upregulation of MIF, THBS1, PDIA3, and
APOA1 and downregulation of EEF2 and FASN in oleate-treated
samples compared to the untreated controls. The data are shown as
the mean ± SEM. *P < 0.05 by Student’s t-test
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rescued by oleate treatment, which supports the promo-
tion of proliferation of HepG2 cells by oleate treatment. In
addition, LC-MS/MS analysis measured caspases 3 and 7,
which are marker proteins for apoptosis, from HepG2
cells with and without the treatment of oleate. We found
that the peptides from these caspases showed no sig-
niﬁcant differences in their abundances between the
oleate-treated cells and untreated controls (Supplemen-
tary Fig. S4a). Moreover, due to the anti-apoptotic effect
of oleate, proportions of the proteins previously reported
to be localized in nonsecretory organelles (cytosol,
nucleus, or mitochondria) can be reduced in oleate-
treated conditions, compared to that in untreated condi-
tions. We thus examined the proportion of proteins in
nonsecretory organelles among 2607 and 2615 protein-
coding genes detected from oleate-treated and untreated
conditions, respectively, and found that the proportions
(67.9%) were similar between the oleate-treated and
untreated conditions (Supplementary Fig. S4b). However,
the effect of oleate on proteins leaked from dying cells can
be reﬂected in their abundances beyond whether they
were detected or not. Thus, we further examined the
proportions of DSPs and non-DSPs in nonsecretory
organelles by the oleate treatment and found that the
proportions were similar between DSPs (69.0%) and non-
DSPs (67.5%) (Supplementary Fig. S4c). All of these data
suggest that no signiﬁcant apoptosis was induced by
oleate and thus no signiﬁcant contamination of the
secretome with the apoptotic content.
We showed that lipid metabolism, inﬂammatory
response, and ER stress were upregulated in the secre-
tome of the oleate-treated HepG2 cells. Previously, the
interplays among these processes have been reported
under pathological conditions, including cardiovascular
diseases and cancers. For example, the interplay between
lipid metabolism and inﬂammation in metabolic tissues
can aggravate the development of atherosclerosis62.
Saturated FAs induce pro-inﬂammatory signaling, while
unsaturated FAs (omega-3 and omega-9 FAs) induce anti-
inﬂammatory signaling62. In particular, oleate was shown
to induce anti-inﬂammatory responses49,50. This anti-
inﬂammatory effect of oleate is consistent with upregu-
lation of molecules associated with the anti-inﬂammatory
response (Fig. 3d) in our secretome. Moreover, the
interplay between lipid metabolism and ER stress was
previously observed in hepatic steatosis63. Similarly,
saturated FAs activated ER stress leading to apoptosis in
steatotic rat liver, but unsaturated FAs (oleate and linoleic
acid) rescued palmitate-induced ER stress and apopto-
sis64. This observation is consistent with the upregulation
of cytoprotective mild ER stress (ER network in Fig. 3e) in
our secretome. Thus, our secretome data suggest that
oleate can induce the interplays among these three pro-
cesses within HepG2 cells. However, the inference of
intracellular regulatory pathways underlying the inter-
plays among these processes still remains challenging due
to limited information that can be used to predict the
intracellular pathways in our secretome data. Never-
theless, the network models revealed an upregulation of
transcription and signaling regulators related to lipid
metabolism (RBP4, AGT, and APOA1), inﬂammation
(SPP1, TGFBR3, and THBS1), and ER stress (HSP90B1,
PDIA3, and PRKCSH), which were upregulated in the
secretome of oleate-treated HepG2 cells, suggesting their
potential roles in the interplays among these processes,
which can be tested in detailed functional experiments.
A number of previous studies have shown associations
of the proteins selected in this study, especially the four
upregulated proteins (MIF, THBS1, PDIA3, and APOA1),
with various features of cancer pathophysiology in liver
cancer, as well as other types of cancers (Supplementary
Table S7): (1) MIF was reported to be increased at both
the mRNA and protein levels in liver cancer tissues
compared to noncancerous tissues65 and to promote
tumor survival, angiogenesis, and/or metastasis in colon,
head and neck, liver, and/or prostate cancers;65–68 (2)
THBS1 was shown to be elevated in liver cancer69 and to
promote tumor survival, aggressiveness, angiogenesis, and
metastasis in breast, bladder, liver, gastric, prostate, and/
or pancreatic cancers;69–74 (3) PDIA3 was reported to be
elevated in liver cancer75 and to enhance the proliferation
of tumor cells, metastasis, and/or invasion in breast,
colon, ovarian, and/or pancreatic cancers;75–79 and (4)
APOA1 was observed to be elevated in the serum of liver
cancer patients80, as well as in the serum of breast, colon,
and lung cancers81–83 and in the urine of bladder can-
cer84, and its abundance showed positive correlations with
aggressiveness and/or metastasis in bladder, colon, and
lung cancers82,85,86. These data suggest that the secreted
proteins with various tumors might serve as a secretome
proﬁle that can represent cancer pathophysiology, such as
the proliferation of tumor cells. However, none of these
secreted proteins have been previously reported to be
altered in their protein levels by the increased FA.
Several proteomic studies have provided the secretomes
of various cancers and/or lists of DSPs in cancers com-
pared to controls (Supplementary Table S8). First, Wu
et al4. provided the secretome of 23 cancer cell lines
derived from 11 types of cancers, which included 4584
non-redundant proteins, and then proposed pan-cancer
markers and also selective markers for each type of can-
cer. In addition, Planque et al87. proﬁled the secretome of
lung cancer cell lines, including 1830 secretory proteins,
and proposed a set of biomarker proteins for lung cancer.
Moreover, Ralhan et al88. identiﬁed 122 secreted proteins
from head and neck cancer cell lines; Sardana et al3.
identiﬁed 2124 secreted proteins from prostate cancer cell
lines; and Gunawardana et al89. identiﬁed 420 secreted
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proteins from ovarian cancer cell lines. Second, a number
of studies have performed comparative secretome ana-
lyses of tumor and normal samples in various types of
cancers, including breast, colon, esophagus, gastric, head
and neck, liver, and pancreatic tumors, providing the lists
of DSPs in these cancer samples compared to normal
controls (Supplementary Table S8). The selected proteins
in this study were detected in many of these previous
secretome studies and further identiﬁed as DSPs in one of
the previous studies. However, their upregulation or
downregulation patterns were different depending on the
type of cancer and cell lines used and/or culture condi-
tions, suggesting that their abundances could be used as
indicators of different conditions in the tumor micro-
environment. Nevertheless, none of the selected proteins
have been previously reported to be altered in their
secretion by increased oleate.
Our study showed differential secretion of the six
selected proteins, which have been previously reported to
be associated with the proliferation of tumor cells, thus
supporting their potential use as an indicator of FA-
induced proliferation of tumor cells. The clinical impli-
cations of these selected proteins can be tested with a
larger number of tumor patients. In addition, longitudinal
studies can be designed to further demonstrate the nature
of the altered secretion of the selected proteins during the
course of tumorigenesis. Additionally, novel subtypes of
liver cancer patients might be further characterized based
on the status of the FA-induced proliferation of tumor
cells or the FA-induced metabolic reprogramming
represented by the proposed secretome proﬁle. In addi-
tion to the selected proteins, our approach provided a
comprehensive list of DSPs associated with lipid meta-
bolism, inﬂammatory response, and ER stress, thus
extensively extending the current list of tumor survival-
related secreted proteins identiﬁed by conventional small-
scale experiments or approaches. This list of secreted
proteins can serve as comprehensive resource to biolo-
gists who study FA-dependent tumor survival. Further-
more, the network models can provide the basis for
an understanding of the roles of secreted proteins in
the FA-induced metabolic reprogramming (Fig. 3c),
inﬂammatory response (Fig. 3d), and ER stress (Fig. 3e)
in tumor survival. The network models further suggested
that lysosomal activation (Fig. 3c) and protein degradation
(Fig. 3e) associated with the DSPs could be involved in
tumor survival. This understanding can further suggest
proactive therapeutic strategies for FA-induced tumor
survival. In summary, our approach successfully identiﬁed
a secretome proﬁle that can provide a novel dimension
of the information indicative of FA-induced tumor
survival for classiﬁcation, therapy, and pathogenesis of
liver cancer.
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